NeuroThera Effectiveness and Safety Trial 3: how do we align corporate and scientific integrity to complete and report pharma-sponsored trials properly?
نویسندگان
چکیده
I n this issue of Stroke, Hacke et al 1 for the NeuroThera Effectiveness and Safety Trial 3 (NEST 3) Committees and Investigators report the results of a phase III, randomized, double blind clinical trial of transcranial laser therapy for acute ischemic stroke. This was a device trial sponsored and funded by industry via venture capital specifically to PhotoThera, Inc, a privately held medical device company. Once the independent Data Monitoring Committee halted the trial for futility, a little more than halfway through recruitment, a drama full of twists and turns played out like a John Grisham novel. The authors of this editorial received further information about the history of the NEST trials to help frame a perspective (Dr Dilly, personal email communication through the Stroke editorial office to NEST 3 was the third clinical study of transcranial laser therapy for stroke conducted by PhotoThera. NEST 1, a phase II study, gave highly encouraging results including a statistically significant improvement in functional outcome 90 days after stroke. PhotoThera raised money from a syndicate of venture capital investors to conduct NEST 2, intended to be the definitive registration trial for transcranial laser therapy. NEST 2 enrolled 660 patients at a cost of ≈$50 million and failed to meet its primary end point. However, further analysis of the trial strongly suggested that a subgroup of the study population with more superficially placed strokes and mild-moderate base-line symptom severity had benefitted from treatment. On the basis of these data, PhotoThera raised an additional ≈$60 million from existing and new investors to fund NEST 3, which was aimed specifically at the subgroup. It is important to understand that $10 million was in the form of venture debt—secured against the intellectual property and assets of PhotoThera. [Venture debt is a type of debt financing for emerging venture-backed companies and is a means of financing start-ups that are in between more traditional venture capital financing rounds. Sometimes companies run short of capital in between funding milestones. Companies who run short of capital are sometimes good candidates for venture debt.] The $60 million raised was projected to be sufficient to fund the NEST 3 study fully. Unfortunately, recruitment into NEST 3 went significantly slower than planned, and site costs were higher than predicted such that PhotoThera was projected to run out of money before the completion of the study. (We are not aware of when they realized …
منابع مشابه
The paroxetine 352 bipolar trial: A study in medical ghostwriting.
BACKGROUND The problem of ghostwriting in corporate-sponsored clinical trials is of concern to medicine, bioethics, and government agencies. We present a study of the ghostwritten archival report of an industry-sponsored trial comparing antidepressant treatments for bipolar depression: GlaxoSmithKline (GSK) paroxetine study 352. This analysis is based upon publicly available evidence presented ...
متن کاملI-31: The Scientific Underpinning of ART in Unexplained Infertility
Although intra uterine insemination (IUI) and in vitro fertilization (IVF) are widely accepted treatments among doctors and patients and practiced on large scale, it is good to realize that they have rarely been evaluated properly in randomized clinical trials or even in comparative cohort studies. Although the first pregnancy after IUI was established in 1884, it was not until 2008 that the fi...
متن کاملEvidence Based Medicine: Clinical Trials
Evidence based medicine is very important for success of modern medicine. It is the ongoing process of using the most reliable evidence from clinical studies, scientific understanding and medical practice to make the best possible medical choice for patients. Evidence based medicine is how medicine advances and how we get improvements in life expectancy and quality of life. It not only identifi...
متن کاملA systematic review and meta-analysis of clinical trials on saffron (Crocus sativus) effectiveness and safety on erectile dysfunction and semen parameters
Objective: We performed this systematic review and meta-analysis study to determine saffron (Crocus sativus) effectiveness and safety in male infertility problems. Materials and Methods: The databases PubMed, Scopus, Cochrane, Google Scholar, SID, IranMedex and Magiran until July 2016 and reference section of relevant articles, were searched to find both English and Persian clinical trials on m...
متن کاملIntroductory editorial to 30th anniversary edition
We are highly privileged to write this editorial at such a significant moment for the Medical Journal of the Islamic Republic of Iran (MJIRI) as this journal celebrates its 30- year tradition as an accessible source of scholarly articles on the basic and clinical medical sciences, rigorously edited, and progressive. The MJIRI was launched by Iran National Center for Scientific Research ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Stroke
دوره 45 11 شماره
صفحات -
تاریخ انتشار 2014